Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study | Trials | Full Text

Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study | Trials | Full Text

Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study

Acute respiratory distress syndrome (ARDS) is caused by rapid-onset (within hours) acute inflammatory processes in lung tissue, and it is a life-threatening condition with high mortality. The treatment of ARDS...

Authors:Helene Haeberle, Stefanie Prohaska, Peter Martus, Andreas Straub, Alexander Zarbock, Gernot Marx, Manola Zago, Martin Giera, Michael Koeppen and Peter Rosenberger

Citation:Trials 2020 21:242

Content type:Study protocol

Published on: 4 March 2020

• ViewFull Text
 
• ViewPDF